G

Geron Corp
D

GERN

1.43000
USD
0.03
(1.78%)
مغلق
حجم التداول
77,101
الربح لكل سهم
-0
العائد الربحي
-
P/E
-7
حجم السوق
910,792,394
أصول ذات صلة
ALNY
ALNY
-4.39
(-1.33%)
325.26 USD
AMGN
AMGN
1.79
(0.60%)
298.52 USD
BMY
BMY
-0.525
(-1.10%)
47.080 USD
C
CLDX
-0.150
(-0.68%)
21.950 USD
GILD
GILD
-0.760
(-0.68%)
110.760 USD
INCY
INCY
0.300
(0.44%)
68.470 USD
المزيد
الأخبار المقالات

العنوان: Geron Corp

القطاع: Healthcare
الصناعة: Biotechnology
Geron Corp is a clinical-stage biopharmaceutical company focused on the research and development of cancer treatments. The company's drug in development, Imelstat, is being tested for the treatment of myelodysplastic syndromes, which are disorders of the blood, and myelofibrosis, which is a rare blood cancer affecting bone marrow. The company earns revenue through collaboration agreements, milestones, royalties, and licensing arrangements. Geron possesses various rights to this drug. The company operates as a single segment being, the development of therapeutic products for oncology.